Literature DB >> 17965313

Missing the point: substituting exenatide for nonoptimized insulin: going from bad to worse!

Julio Rosenstock, Vivian Fonseca.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17965313     DOI: 10.2337/dc07-1592

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


× No keyword cloud information.
  5 in total

1.  Liraglutide administration in type 2 diabetic patients who either received no previous treatment or were treated with an oral hypoglycemic agent showed greater efficacy than that in patients switching from insulin.

Authors:  Takuo Nambu; Yuki Matsuda; Koji Matsuo; Yugo Kanai; Shin Yonemitsu; Seiji Muro; Shogo Oki
Journal:  J Diabetes Investig       Date:  2012-09-07       Impact factor: 4.232

2.  Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial).

Authors:  Marcus Lind; Irl B Hirsch; Jaakko Tuomilehto; Sofia Dahlqvist; Bo Ahrén; Ole Torffvit; Stig Attvall; Magnus Ekelund; Karin Filipsson; Bengt-Olov Tengmark; Stefan Sjöberg; Nils-Gunnar Pehrsson
Journal:  BMJ       Date:  2015-10-28

Review 3.  Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature.

Authors:  R Balena; I E Hensley; S Miller; A H Barnett
Journal:  Diabetes Obes Metab       Date:  2012-11-12       Impact factor: 6.577

4.  Efficacy and safety of lixisenatide once-daily morning or evening injections in type 2 diabetes inadequately controlled on metformin (GetGoal-M).

Authors:  Bo Ahrén; Aniceto Leguizamo Dimas; Patrick Miossec; Stéphane Saubadu; Ronnie Aronson
Journal:  Diabetes Care       Date:  2013-03-27       Impact factor: 19.112

5.  Comparison of insulin lispro protamine suspension versus insulin glargine once daily added to oral antihyperglycaemic medications and exenatide in type 2 diabetes: a prospective randomized open-label trial.

Authors:  R F Arakaki; T C Blevins; J K Wise; D R Liljenquist; H H Jiang; J G Jacobson; S A Martin; J A Jackson
Journal:  Diabetes Obes Metab       Date:  2013-12-29       Impact factor: 6.577

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.